Clonidine vs Guanfacine: Key Differences for ADHD and Beyond
Author:
Blossom Editorial
Clonidine and guanfacine are closely related medications called alpha-2 adrenergic agonists. They were originally developed to treat high blood pressure, and extended-release versions of each are now FDA-approved as non-stimulant treatments for ADHD in children and adolescents ages 6-17. While they work in similar ways, they differ in how selective they are, how often they're taken, and which side effects are most common.
Key Takeaways
Both are established non-stimulant ADHD treatments: Extended-release clonidine and guanfacine are FDA-approved for ADHD in ages 6 to 17, either alone or added to a stimulant.
Guanfacine is more selective, while clonidine acts more broadly: That difference may help explain why clonidine tends to cause more sedation and drops in blood pressure, though sleepiness is common with both.
Neither should be stopped suddenly: Abrupt discontinuation can cause blood pressure and heart rate to rise, sometimes significantly. Your prescriber can develop a tapering plan and monitor your blood pressure and pulse during the process.
What are Clonidine and Guanfacine?
Both medications belong to a class called alpha-2 adrenergic agonists. This means that they act predominantly on alpha-2 receptors in an area of the brain known as the prefrontal cortex. This is thought to help regulate attention, impulse control, and blood pressure. Each comes in immediate-release and extended-release (ER) forms with different approved uses.
Clonidine (Catapres): Immediate-release clonidine is approved to treat hypertension and has been used in the U.S. since 1974.
Clonidine ER (Kapvay): The extended-release version is approved for ADHD in patients ages 6 to 17, as monotherapy or alongside stimulants.
Guanfacine (Tenex): Immediate-release guanfacine is approved for managing hypertension.
Guanfacine ER (Intuniv): The extended-release version is approved for ADHD in ages 6 to 17, alone or with a stimulant.
Both ER medications are part of a broader group of non-stimulant ADHD medications, which also includes atomoxetine (Strattera)and viloxazine (Qelbree).
Clonidine vs Guanfacine at a Glance
Before getting into the details, this side-by-side summary highlights the main differences between the extended-release ADHD versions.
Feature | Clonidine ER (Kapvay) | Guanfacine ER (Intuniv) |
|---|---|---|
Receptor targets | Alpha-2A, 2B, and 2C | Mainly alpha-2A |
Dosing schedule | Twice daily | Once daily, either morning or evening |
Starting dose | 0.1 mg at bedtime | 1 mg per day |
Typical dose range | Up to 0.4 mg per day in two divided doses | 1 to 7 mg per day, based on weight |
Approximate half-life | About 12.7 hours | About 17 hours |
Most common side effect | Sleepiness | Sleepiness, low blood pressure |
Clonidine vs Guanfacine: Key Differences
While both medications act on alpha-2 receptors, several practical differences may influence which one a provider recommends.
Receptor Selectivity
Clonidine stimulates alpha-2A, alpha-2B, and alpha-2C receptors, while guanfacine preferentially targets the alpha-2A subtype. In fact, guanfacine is reported to have 15-20 times greater affinity for alpha-2A receptors compared to the other two subtypes, and may be less sedating for some people than clonidine due to its more focused action. In addition, clonidine also acts on imidazoline receptors, which may also contribute to its blood pressure-lowering properties.
Dosing Schedule
According to the FDA prescribing information, Clonidine ER (Kapvay) is taken twice a day, with an equal or larger dose at bedtime. Treatment starts with 0.1 mg at bedtime and increases by 0.1 mg per week, and doses above 0.4 mg per day haven’t been studied.
Guanfacine ER (Intuniv) is taken once a day. Per the FDA label, it starts at 1 mg and increases by no more than 1 mg per week, with a recommended range of 1 to 7 mg based on body weight. More specifically, the recommended target dose is 0.05-0.12 mg/kg/day, adjusted for response and tolerability. Moreover, doses above 4 mg/day have not been evaluated in children ages 6-12, and doses above 7 mg/day have not been evaluated in adolescents ages 13-17.
Some people may find Guanfacine ER’s once-daily dosing easier to stick with.
Side Effects
Sleepiness is one of the most frequently reported side effects of both medications in pediatric ADHD trials. In an eight-week clinical trial of clonidine ER (Kapvay) used alone, somnolence affected 31% (on 0.4 mg) to 38% (on 0.2 mg) of patients, compared with 4% on placebo. In fixed-dose trials of guanfacine ER (Intuniv), somnolence affected 38% of patients on average, compared with 11% on placebo.
Guanfacine ER displayed a dose-dependent effect on sedation, with higher doses associated with a higher percentage of patients reporting sedation. The figures ranged from 28% on 1 mg to 51% on 4 mg.
Since the trials of clonidine ER and guanfacine ER weren’t head-to-head, it’s not possible to compare these figures and conclude that one is more sedating than the other.
Other common side effects of both include:
Fatigue
Dry mouth
Dizziness
Low blood pressure (hypotension)
Slow heart rate (bradycardia)
Some users of clonidine ER may experience a stronger hypotensive and bradycardic effect, which could be due to its activity at imidazoline receptors and a broader effect at alpha-2 receptors, compared to guanfacine ER, which is selective towards the alpha-2A receptor.
Headache, constipation, and upper abdominal pain were other side effects reported with clonidine ER, while guanfacine ER users reported nausea and lethargy as other side effects. The likelihood of each effect varies by medication, dose, and individual response.
Some side effects often ease as the body adjusts, while others can persist. Taking doses at bedtime may help with daytime sleepiness. If sedation interferes with daily activities, contact your prescriber and do not change dose or timing on your own.
Half-Life and Duration
The elimination half-life of guanfacine is about 16 to 17 hours with the extended-release form, compared with roughly 12.7 hours for clonidine ER. A longer half-life supports once-daily dosing.
Clonidine vs Guanfacine for ADHD: Which Works Better?
Clinical trials support both medications as treatments for ADHD in children and adolescents, either alone or alongside stimulant medication. However, evidence from comparative studies generally indicates that stimulants have larger average short-term effects on core ADHD symptoms. Individual responses vary, and non-stimulants may be useful when stimulants are ineffective, poorly tolerated, or unsuitable.
Overall effect: A 2014 meta-analysis of 12 studies including 2,276 young people found that alpha-2 agonists reduced ADHD symptoms when used alone, and providedr additional symptom improvement when added to stimulants. However, effect sizes of alpha-2 agonists when used as add-on treatment were lower than with monotherapy.
Head-to-head comparisons: No large head-to-head trials directly compare the two, but a large 2018 network meta-analysis found similar symptom improvements in children for clonidine and guanfacine compared with placebo.
Clinical guidelines: The American Academy of Pediatrics recognizes extended-release guanfacine and clonidine as evidence-supported options for pediatric ADHD, including as add-on treatments when a stimulant alone does not provide sufficient benefit or is limited by side effects. However, the evidence base for stimulants is larger, and stimulants remain the better-established first-line pharmacologic option for many children and adolescents.
Stimulant comparison: The CDC reports that approximately 70% to 80% of children with ADHD have fewer symptoms when taking stimulant medication. Non-stimulants generally have a slower onset of clinical benefit, although extended-release formulations of some non-stimulants can provide effects lasting up to 24 hours.
The trade-offs between stimulant vs. non-stimulant ADHD medications often guide which one a provider tries first.
Can Adults Take Clonidine or Guanfacine for ADHD?
In the U.S., neither clonidine ER nor guanfacine ER is FDA-approved for ADHD in adults. The 2018 meta-analysis reviewed several ADHD medications and found no studies testing these two drugs in adults at the time.
Newer research is emerging. A 2020 randomized, placebo-controlled trial of over 200 Japanese adults found that guanfacine ER improved ADHD symptoms. Adverse events were common, and discontinuations due to adverse events occurred more often with guanfacine than placebo. The results support potential efficacy in adults but do not establish long-term effectiveness or tolerability in all populations.
Some U.S. providers prescribe these medications off-label for adults, particularly when stimulants aren't a good fit.
Other Uses for Clonidine and Guanfacine
Beyond ADHD and blood pressure, providers sometimes prescribe these medications for other conditions. Some of these uses are off-label, meaning they aren't specifically FDA-approved.
Tic Disorders and Tourette Syndrome
For people with ADHD and co-occurring tic disorders, alpha-2 agonists such as clonidine or guanfacine may help reduce ADHD symptoms and, in some cases, tic severity. The choice of medication should account for the individual's symptoms, adverse effects, and cardiovascular health. Heart rate and blood pressure should be monitored, and these medications should be tapered rather than stopped abruptly.
Opioid Withdrawal
Clonidine is used off-label to ease opioid withdrawal symptoms. A related medication, lofexidine, was approved in 2018 as the first medication for mitigating opioid withdrawal symptoms in adults. Evidence suggests lofexidine may cause less hypotension than clonidine, but both can cause low blood pressure and other adverse effects. Neither medication replaces comprehensive treatment for opioid use disorder.
Other Off-Label Uses of Clonidine
Clonidine has also been used off-label for anxiety, menopausal hot flashes, restless legs, and migraine prevention, as well as withdrawal from alcohol and benzodiazepines. Evidence for these uses varies, and clonidine is not a first-line treatment for many of these uses. It may reduce some physical symptoms of withdrawal but does not replace treatments needed to prevent serious complications.
Clonidine and Guanfacine Safety Considerations
Both medications are generally well tolerated, but there are important safety points to keep in mind.
Don't stop suddenly: Do not stop clonidine ER or guanfacine ER suddenly without medical guidance. To reduce the risk of rebound hypertension, the prescribing information recommends tapering clonidine ER by no more than 0.1 mg every 3 to 7 days, and guanfacine ER by no more than 1 mg every 3 to 7 days. Your prescriber should individualize the taper and monitor blood pressure and pulse during discontinuation.
Heart rate and blood pressure: Your prescriber should check your blood pressure and heart rate before treatment, after dose increases, and periodically during treatment. More frequent monitoring may be needed if you have cardiovascular conditions, a history of fainting, or take other medicines that lower blood pressure or heart rate.
Drowsiness: Since sedation is a well-known side effect of these medications, use caution with driving or other activities that need alertness until you know how the medication affects you.
Other sedating substances: Alcohol and other sedating medications may add to drowsiness and impair alertness when taken with clonidine or guanfacine. Ask your prescriber or pharmacist about alcohol and other sedating substances, and avoid driving or operating machinery until you know how the medication affects you.
Avoid high-fat meals when taking guanfacine ER: High-fat meals can increase guanfacine absorption and blood levels, potentially increasing the risk of side effects such as low blood pressure, a slow heart rate, dizziness, and excessive sleepiness. Take guanfacine consistently as directed by your prescriber and follow the medication guide’s instructions regarding food.
Breastfeeding: There is limited information about guanfacine use during breastfeeding. A better-studied alternative may be preferred, particularly for a newborn or preterm infant. Clonidine use during pregnancy requires an individualized risk-benefit assessment because evidence on its effects is limited. During breastfeeding, alternative antihypertensive medications are generally preferred, especially for newborns and preterm infants, because clonidine can reach measurable levels in breastfed infants and may cause adverse effects or affect milk production.
When to Contact Your Provider About Clonidine or Guanfacine
Contact your provider if you're taking clonidine or guanfacine and notice:
Fainting, severe dizziness, or lightheadedness when standing (orthostatic hypotension).
A very slow or irregular heartbeat.
Sleepiness that interferes with school, work, or driving.
Headache, nervousness, or a racing heart after missing doses, which can indicate rebound hypertension. More importantly, seek medical guidance about restarting or adjusting your medication rather than doubling a dose.
ADHD symptoms that aren't improving after several weeks.
If you have chest pain, trouble breathing, or fainting, seek emergency care right away.
How Blossom Health Can Help With ADHD Medication Decisions
Choosing between clonidine, guanfacine, and other ADHD treatments depends on your symptoms, age, health history, and goals. Blossom Health connects you with board-certified, licensed psychiatric providers for virtual care. .During your first hour-long video visit, your provider will review your history, symptoms, and goals, make a diagnosis if appropriate, and build a treatment plan that may include medication.
If another type of care would be a better fit, your provider will help point you there. Blossom works with many insurance plans, and you can check your coverage before scheduling your first appointment. Most patients are often seen within days.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. If you are experiencing a mental health crisis, call or text the 988 Suicide and Crisis Lifeline.
Sources
1. U.S. Food and Drug Administration. Treating and dealing with ADHD. https://www.fda.gov/consumers/consumer-updates/treating-and-dealing-adhd
2. Neuchat, E. E., Bocklud, B. E., Kingsley, K., et al. (2023). The role of alpha-2 agonists for attention deficit hyperactivity disorder in children: A review. Neurology International, 15(2), 697-707. https://pmc.ncbi.nlm.nih.gov/articles/PMC10204383/#B5-neurolint-15-00043
3. U.S. Food and Drug Administration. (2020). Kapvay (clonidine hydrochloride) extended-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf
4. U.S. Food and Drug Administration. (2012). Catapres (clonidine hydrochloride) tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017407s037lbl.pdf
5. U.S. Food and Drug Administration. (July, 2013). Tenex (guanfacine hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf
6. Patel, P., & Saadabadi, A. (December 13, 2025). Clonidine. StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459124/
7. National Institute of Diabetes and Digestive and Kidney Diseases. (August 25, 2021). Clonidine. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548329/
8. Shire US Inc. (2019). Intuniv (guanfacine) extended-release tablets: Prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf
9. National Institute of Child Health and Human Development. (November 15, 2024). Guanfacine. Drugs and Lactation Database (LactMed). https://www.ncbi.nlm.nih.gov/books/NBK501522/
10. Cruz M. P. (2010). Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder. P & T : a peer-reviewed journal for formulary management, 35(8), 448–451. https://pmc.ncbi.nlm.nih.gov/articles/PMC2935643
11. Reis, D. J., & Piletz, J. E. (1997). The imidazoline receptor is in control of blood pressure by clonidine and allied drugs. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 273(5), R1569–R1571. https://journals.physiology.org/doi/full/10.1152/ajpregu.1997.273.5.R1569
12. Hirota, T., Schwartz, S., & Correll, C. U. (2014). Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: A systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. Journal of the American Academy of Child and Adolescent Psychiatry, 53(2), 153-173. https://academicworks.medicine.hofstra.edu/articles/1028/
13. Cortese, S., Adamo, N., Del Giovane, C., et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727-738. https://vbn.aau.dk/ws/files/287574297/1_s2.0_S2215036618302694_main.pdf
14. Wolraich, M. L., Hagan, J. F., Allan, C., et al. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://stacks.cdc.gov/view/cdc/85858/cdc_85858_DS1.pdf
15. Iwanami, A., Saito, K., Fujiwara, M., Okutsu, D., & Ichikawa, H. (2020). Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 81(3), 19m12979. https://www.psychiatrist.com/JCP/article/Pages/2020/v81/19m12979.aspx
16. Ota, T., Yamamuro, K., Okazaki, K., & Kishimoto, T. (2021). Evaluating guanfacine hydrochloride in the treatment of ADHD in adult patients: Design, development and place in therapy. Drug Design, Development and Therapy, 15, 1965-1969. https://www.dovepress.com/article/download/64649
17. Pringsheim, T., Okun, M. S., Müller-Vahl, K., et al. (2019). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92(19), 896-906. https://depts.washington.edu/dbpeds/TS%5BPringsheim2019-New%20Practice%20Guidelines%5D.pdf
18. Bryce, C. (2019). Lofexidine (Lucemyra) for treatment of opioid withdrawal symptoms. American Family Physician, 99(6), 392-394. https://www.aafp.org/pubs/afp/issues/2019/0315/p392.html
19. Centers for Disease Control and Prevention. (July 30, 2026). Treatment of ADHD. https://www.cdc.gov/adhd/treatment/index.html
20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Clonidine. [Updated 2024 Nov 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501628/
